CA2999937A1 - New pyrrolo[2,3-d]pyrimidine derivatives as dual dyrk1/clk1 inhibitors - Google Patents

New pyrrolo[2,3-d]pyrimidine derivatives as dual dyrk1/clk1 inhibitors Download PDF

Info

Publication number
CA2999937A1
CA2999937A1 CA2999937A CA2999937A CA2999937A1 CA 2999937 A1 CA2999937 A1 CA 2999937A1 CA 2999937 A CA2999937 A CA 2999937A CA 2999937 A CA2999937 A CA 2999937A CA 2999937 A1 CA2999937 A1 CA 2999937A1
Authority
CA
Canada
Prior art keywords
pyrrolo
methyl
formula
pyrimidin
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2999937A
Other languages
English (en)
French (fr)
Inventor
Andrea Fiumana
Nicolas Foloppe
Stuart Ray
David Walmsley
Andras Kotschy
Michael Frank Burbridge
Francisco Humberto CRUZALEGUI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Vernalis R&D Ltd
Original Assignee
Les Laboratoires Servier SAS
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS, Vernalis R&D Ltd filed Critical Les Laboratoires Servier SAS
Publication of CA2999937A1 publication Critical patent/CA2999937A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2999937A 2015-09-30 2016-09-30 New pyrrolo[2,3-d]pyrimidine derivatives as dual dyrk1/clk1 inhibitors Abandoned CA2999937A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1559259A FR3041640B1 (fr) 2015-09-30 2015-09-30 NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
FR15/59259 2015-09-30
PCT/EP2016/073403 WO2017055533A1 (en) 2015-09-30 2016-09-30 New pyrrolo[2,3-d]pyrimidine derivatives as dual dyrk1/clk1 inhibitors

Publications (1)

Publication Number Publication Date
CA2999937A1 true CA2999937A1 (en) 2017-04-06

Family

ID=54979756

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2999937A Abandoned CA2999937A1 (en) 2015-09-30 2016-09-30 New pyrrolo[2,3-d]pyrimidine derivatives as dual dyrk1/clk1 inhibitors

Country Status (26)

Country Link
US (1) US20180273538A1 (enExample)
EP (1) EP3356364A1 (enExample)
JP (1) JP2018533552A (enExample)
KR (1) KR20180054856A (enExample)
CN (1) CN108137582A (enExample)
AU (1) AU2016333508A1 (enExample)
BR (1) BR112018005851A2 (enExample)
CA (1) CA2999937A1 (enExample)
CL (1) CL2018000786A1 (enExample)
CO (1) CO2018003466A2 (enExample)
CR (1) CR20180176A (enExample)
CU (1) CU20180027A7 (enExample)
DO (1) DOP2018000082A (enExample)
EA (1) EA201890820A1 (enExample)
EC (1) ECSP18023286A (enExample)
FR (1) FR3041640B1 (enExample)
HK (1) HK1255467A1 (enExample)
IL (1) IL258231A (enExample)
MA (1) MA43021A (enExample)
MX (1) MX2018003861A (enExample)
NI (1) NI201800042A (enExample)
PE (1) PE20190337A1 (enExample)
PH (1) PH12018500605A1 (enExample)
SV (1) SV2018005656A (enExample)
TN (1) TN2018000087A1 (enExample)
WO (1) WO2017055533A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11524968B2 (en) 2017-10-18 2022-12-13 Hk Inno.N Corporation Heterocyclic compound as a protein kinase inhibitor
US12180185B2 (en) 2018-11-15 2024-12-31 Hk Inno.N Corporation Compound as protein kinase inhibitor, and pharmaceutical composition comprising thereof

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102054910B1 (ko) * 2017-12-19 2019-12-12 한림제약(주) 피롤로[2,3-d]피리미딘 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
US12528810B2 (en) 2018-03-01 2026-01-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK/CLK and uses thereof
US12054483B2 (en) 2018-09-28 2024-08-06 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK/CLK and uses thereof
PE20211655A1 (es) 2018-10-31 2021-08-24 Gilead Sciences Inc Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
CN110407744A (zh) * 2019-08-13 2019-11-05 上海毕得医药科技有限公司 一种1-(4-氨基吡啶-2-基)乙酮的合成方法
AR120799A1 (es) * 2019-12-20 2022-03-16 Hoffmann La Roche 2-[4-cloro-6-[2-[4-[[4-(hidroximetil)-1-piperidil]metil]fenil]etinil]-1-oxoisoindolin-2-il]-2-(6,7-dihidro-5h-pirrolo[1,2-c]imidazol-1-il)-n-tiazol-2-il-acetamida como inhibidor de egfr
WO2022117012A1 (zh) * 2020-12-02 2022-06-09 百极弘烨（广东）医药科技有限公司 螺环jak抑制剂、含其的药物组合物及其应用
WO2022245776A1 (en) * 2021-05-20 2022-11-24 Saint John's Cancer Institute Anti-cdk inhibitors for cancer treatment
CA3234937A1 (en) * 2021-10-12 2023-04-20 Biosplice Therapeutics, Inc. 7h-pyrrolo[2,3-d]pyrimidines and preparation as dyrk1a inhibitors
EP4415817A1 (en) * 2021-10-12 2024-08-21 BioSplice Therapeutics, Inc. 1h-pyrrolo[2,3-b]pyridines as dyrk1a inhibitors
UY39979A (es) 2021-10-12 2023-04-14 Biosplice Therapeutics Inc Pirrolo[2,1-f][1,2,4]triazinas y preparación y usos de las mismas
WO2023110843A1 (en) * 2021-12-15 2023-06-22 Almirall, S.A. Heterobicyclic derivatives as itk inhibitors
CN116621843B (zh) * 2022-06-13 2024-05-24 四川大学华西医院 一种dna甲基转移酶1抑制剂及其制备方法和用途
CN115785134B (zh) * 2022-10-28 2023-08-29 浙大城市学院 一种含氮杂环的硼酸化合物及制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5148499B2 (ja) 2005-05-20 2013-02-20 メチルジーン インコーポレイテッド Ｖｅｇｆ受容体およびｈｇｆ受容体シグナル伝達の阻害剤
US20080004295A1 (en) 2005-10-13 2008-01-03 Gore Paul M Novel compounds
JP2009533323A (ja) 2006-03-11 2009-09-17 ヴァーナリス アールアンドディー リミテッド Ｈｓｐ９０阻害剤として用いられるピロロピリミジン誘導体
FR2912744B1 (fr) * 2007-02-16 2012-09-07 Centre Nat Rech Scient Composes pyrrolo°2,3-b!pyridine,composes azaindoles utiles dans la synthese de ces composes pyrrolo°2,3-b!pyridine, leurs procedes de fabrication et leurs utilisations.
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
MD20140130A2 (ro) * 2012-06-29 2015-04-30 Pfizer Inc. 4-(amino-substituite)-7H-pirolo[2,3-d]pirimidine noi ca inhibitori de LRRK2
WO2015092592A1 (en) * 2013-12-17 2015-06-25 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11524968B2 (en) 2017-10-18 2022-12-13 Hk Inno.N Corporation Heterocyclic compound as a protein kinase inhibitor
US12180185B2 (en) 2018-11-15 2024-12-31 Hk Inno.N Corporation Compound as protein kinase inhibitor, and pharmaceutical composition comprising thereof

Also Published As

Publication number Publication date
MA43021A (fr) 2018-08-08
FR3041640B1 (fr) 2019-05-17
EP3356364A1 (en) 2018-08-08
CR20180176A (es) 2018-05-31
BR112018005851A2 (pt) 2018-10-09
CN108137582A (zh) 2018-06-08
HK1255467A1 (zh) 2019-08-16
KR20180054856A (ko) 2018-05-24
CU20180027A7 (es) 2018-07-05
DOP2018000082A (es) 2018-10-15
MX2018003861A (es) 2018-08-16
NI201800042A (es) 2018-06-21
WO2017055533A1 (en) 2017-04-06
CO2018003466A2 (es) 2018-07-10
FR3041640A1 (enExample) 2017-03-31
PE20190337A1 (es) 2019-03-07
PH12018500605A1 (en) 2018-09-24
TN2018000087A1 (en) 2019-07-08
SV2018005656A (es) 2018-08-10
IL258231A (en) 2018-05-31
AU2016333508A1 (en) 2018-04-12
ECSP18023286A (es) 2018-04-30
EA201890820A1 (ru) 2018-10-31
US20180273538A1 (en) 2018-09-27
CL2018000786A1 (es) 2018-09-28
JP2018533552A (ja) 2018-11-15

Similar Documents

Publication Publication Date Title
EP3356364A1 (en) New pyrrolo[2,3-d]pyrimidine derivatives as dual dyrk1/clk1 inhibitors
CN107108648B (zh) 作为ERK抑制剂的噻吩并[2,3-c]吡咯-4-酮衍生物
EP3442980B1 (en) Heterocyclic compounds as ret kinase inhibitors
CA3214040A1 (en) Inhibiting ubiquitin-specific protease 1 (usp1)
JP6216791B2 (ja) 阻害剤化合物
JP6297570B2 (ja) 薬理活性化合物
JP2021514359A (ja) キナーゼ阻害剤としての複素環式化合物
JP2018150358A (ja) Ｔａｎｋ結合キナーゼインヒビター化合物
CA3150689A1 (en) Heterocyclic compounds as kinase inhibitors
JP6440728B2 (ja) Ｎ２−フェニル−ピリド［３，４−ｄ］ピリミジン−２，８−ジアミン誘導体およびｍｐｓ１阻害剤としてのそれらの使用
KR20230035236A (ko) 아데노신 a2a 수용체의 길항제
AU2005260077A1 (en) Furanopyrimidines
AU2014250836A1 (en) Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways
CN115244050B (zh) 新型hpk1抑制剂及其制备方法和应用
KR20220085735A (ko) 아이소옥사졸리딘 유도체 화합물 및 이의 용도
AU2016333505A1 (en) New imidazo(4,5-B)pyridine derivatives as dual DYRK1/CLK1 inhibitors
WO2016090079A1 (en) Heteroaryl compounds and uses thereof
CA3049820A1 (en) Compounds for inhibiting lrrk2 kinase activity
WO2022236256A1 (en) Heterocyclic compounds as kinase inhibitors
KR20220123446A (ko) Btk 억제제
OA18644A (en) New pyrrolo[2,3-d]pyrimidine derivatives as dual DYRK1/CLK1 inhibitors.
Li et al. Development of novel palbociclib-based CDK4/6 inhibitors exploring the back pocket behind the gatekeeper
RU2802866C2 (ru) Соединения триазоло-пиримидина и их применение
RU2802866C9 (ru) Соединения триазоло-пиримидина и их применение
WO2026021570A1 (en) Btk degrader and use thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180326

FZDE Discontinued

Effective date: 20200831